Allrock Bio
allrockbio.com
Actively hiring
Biotechnology
Drug Discovery
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$50M
1 round on record
Latest round
$50M
Series A · Sep 2025 · 12 mo ago
Team
51-200
employees, estimated range
Backers
1
Westlake BioPartners
The money's age
Due for its next round
12 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 15, 2025
Raised a round Series A $50M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Sep 2025 | $50M | — | medindia.net |
Backed byfrom the funds' portfolios and accelerator catalogs
Westlake BioPartners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Our team has extensive expertise in kidney disease, targeted delivery of RNA therapeutics, translational systems biology and data sciences…
Soricimed Biopharma is a clinical stage drug development company dedicated to novel trageted treatments for cancer.
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
Babylon is a drug development company pursuing a transformational treatment for Alzheimer’s. Meet our team and explore how we discover…
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological…
Our goal is to streamline drug development in order to accelerate patient access to important medical therapies.
Overview
AllRock Bio is leveraging extensive expertise from drug development to commercialization. AllRock Bio’s team is dedicated to advancing impactful therapies for cardiopulmonary diseases.
News
AllRock Bio Announces $50 Million Series A Funding Aimed at Advancing Leading Molecule Roc-101 PharmExec
AllRock Bio secures $50 million to advance Roc-101, a promising treatment for pulmonary hypertension, aiming to transform patient care.
Read more
Report
AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension
AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and fibrotic diseases, today announced the dosing of the first patients in the Phase 2a ROCSTAR trial of ROC-101, a first-in-class, oral
Read more
Report
AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension
/PRNewswire/ -- AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and fibrotic diseases,...
Read more
Report
Report
AllRock Bio presents phase 1 data for lead programme, ROC-101 at the ERS Congress
AllRock Bio presents phase 1 data for lead programme, ROC-101 at the ERS Congress
Read more
Report
AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress
/PRNewswire/ -- AllRock Bio, Inc., a clinical stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and fibrotic diseases,...
Read more
Report
AllRock Bio: $50 Million Series A Raised For Advancing Lead Clinical Program For Pulmonary Hypertension
AllRock Bio has secured $50 million in a Series A funding round led by Versant Ventures and Westlake BioPartners. This funding will support the company as it moves its lead drug candidate, ROC-101, into Phase 2 clinical trials later this year. ROC-101 is
Read more
Report
AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
/PRNewswire/ -- AllRock Bio Inc., a clinical-stage biotechnology company focused on advancing therapies for cardiopulmonary and fibrotic diseases, today...
Read more
Report
Financials
Total raised
$50M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $50M | Details |